Geller Advisors LLC Lowers Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Geller Advisors LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,397 shares of the medical research company’s stock after selling 79 shares during the quarter. Geller Advisors LLC’s holdings in IQVIA were worth $331,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA in the third quarter valued at about $27,000. Park Place Capital Corp acquired a new position in IQVIA during the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA during the 2nd quarter worth approximately $29,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at approximately $32,000. Finally, Avior Wealth Management LLC boosted its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Up 1.9 %

Shares of IQVIA stock opened at $206.57 on Tuesday. The firm has a market cap of $37.49 billion, a PE ratio of 27.11, a P/E/G ratio of 2.08 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The business’s fifty day moving average is $214.57 and its two-hundred day moving average is $224.96.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research analyst reports. The Goldman Sachs Group decreased their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Leerink Partners reissued an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Barclays reduced their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. lowered their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Finally, Robert W. Baird decreased their target price on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.